Oncotarget

Research Papers:

Prognostic role of N-Acetylgalactosaminyltransferase 10 in metastatic renal cell carcinoma

Li Liu, Ying Xiong, Wei Xi, Jiajun Wang, Yang Qu, Zhiyuan Lin, Xiang Chen, Jiaxi Yao, Jiejie Xu and Jianming Guo _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:14995-15003. https://doi.org/10.18632/oncotarget.14786

Metrics: PDF 1681 views  |   HTML 1956 views  |   ?  


Abstract

Li Liu1,*, Ying Xiong1,*, Wei Xi1,*, Jiajun Wang1, Yang Qu1, Zhiyuan Lin1, Xiang Chen1, Jiaxi Yao1, Jiejie Xu2, Jianming Guo1

1Department of Urology, Zhongshan Hospital, Fudan University, Shanghai 200032, China

2Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China

*These authors contributed equally to this work

Correspondence to:

Jiejie Xu, email: [email protected]

Jianming Guo, email: [email protected]

Keywords: metastatic renal cell carcinoma, GALNT10, prognosis, biomarker, tyrosine kinase inhibitors

Received: November 11, 2016     Accepted: January 11, 2017     Published: January 21, 2017

ABSTRACT

Background and Purpose: A previous study demonstrated that GALNT10 affects the sensitivity of cancer cells to tyrosine kinase inhibitor (TKI) therapy. The aim of this study was to assess whether GALNT10 holds a prognostic role in metastatic renal cell carcinoma (mRCC) patients treated with TKI agents.

Results: GALNT10 had no statistical correlation with any other clinicopathological parameters except for route of gaining samples (P = 0.001) and Heng's risk stratification (P = 0.011). Patients with high level of GALNT10 had significantly shorter overall survival (OS) (P < 0.001) and progression-free survival (PFS) (P = 0.002). Importantly, this relationship existed in OS and PFS analyses in sunitinib-treated patients and in OS analyses in sorafenib-treated patients (P = 0.024). In contrast to sorafenib group, percentage of partial response (PR) and stable disease (SD) were higher in sunitinib group, while percentage of progression disease (PD) was much lower. Univariate and multivariate analyses identified that GALNT10 was an independent prognostic factor for OS (HR = 1.938, P = 0.014), not for PFS (HR = 1.532, P = 0.065), in mRCC. Incorporating it into Heng's risk model could sharpen its efficacy in distinguishing patients with potential higher risk.

Materials and Methods: We retrospectively enrolled 138 mRCC patients treated with sunitinib or sorafenib at Zhongshan Hospital, Shanghai, China. A total of 111 valid cases were finally applied for analyses.

Conclusions: These findings suggest that GALNT10 could be applied as a prognostic marker for OS in mRCC patients.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 14786